Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).

Expert opinion on therapeutic targets - 1 Apr 2020

Abati Elena, Bresolin Nereo, Comi Giacomo, Corti Stefania

Abstract excerpt

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and incurable neurodegenerative disorder that targets upper and lower motor neurons and leads to fatal muscle paralysis. Mutations in the superoxide dismutase 1 (SOD1) gene are responsible for 15% of familial ALS cases, but several studies have indicated that SOD1 dysfunction may also play a pathogenic role in sporadic ALS. SOD1 induces numerous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation

Share to Gene Silencing

Share to Molecular Targeted Therapy

Share to Oligonucleotides, Antisense

Share to RNA Interference

Share to Superoxide Dismutase-1

Source

Identifiers

PMID: 32125907
DOI: 10.1080/14728222.2020.1738390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).PMID 32125907Read ↗

Silencing strategies for therapy of SOD1-mediated ALS.Semantic proximity Read ↗

RNA interference and amyotrophic lateral sclerosis.Semantic proximity Read ↗

Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.Semantic proximity Read ↗

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide Dismutase 1-mutated Amyotrophic Lateral Sclerosis: Focus on TofersenSemantic proximity Read ↗

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.Semantic proximity Read ↗

Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing NeuroprotectionSemantic proximity Read ↗

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.Semantic proximity Read ↗

Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.Semantic proximity Read ↗

RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS miceSemantic proximity Read ↗

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosisSemantic proximity Read ↗

SOD1 silencing in motoneurons or glia rescues neuromuscular function in <scp>ALS</scp> miceSemantic proximity Read ↗

Gene Therapy in Amyotrophic Lateral SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.